Compare Heron Therapeutics Inc (HRTX) vs JPMorgan Ultra Short Income ETF (JPST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs JPMorgan Ultra Short Income ETF — how do they compare? Heron Therapeutics Inc trades at $0.37 (market cap $74.04M), while JPMorgan Ultra Short Income ETF trades at $50.28 (market cap $42.37B). The key difference: JPMorgan Ultra Short Income ETF is far larger — about 572.3× Heron Therapeutics Inc's market cap, and JPMorgan Ultra Short Income ETF is more actively traded (6,289,709 versus 3,668,095). Which is the better fit depends on your goals — on Pluang, investors hold Heron Therapeutics Inc for 35 Days and JPMorgan Ultra Short Income ETF for 46 Days on average.
| HRTX | JPST | |
|---|---|---|
Market Cap | $74.04M | $42.37B |
Volume | 3,668,095 | 6,289,709 |
Sector | Health | Fixed Income |
52-Week High | $1.49 | $50.78 |
52-Week Low | $0.27 | $50.22 |
Typical Hold Time | 35 Days | 46 Days |
Enterprise Value | $180.78M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HRTX trades at $0.39, up 17.58% today, with a bullish technical signal from moving averages. The company reported Q2 2026 revenue of $37.7 million but missed EPS estimates with a $0.03 loss. Despite negative profitability metrics, analyst consensus remains strongly positive with 89% buy ratings. Recent news highlights ongoing comparisons with peers and earnings performance discussions.
The outlook is mixed: strong analyst support and technical momentum suggest potential upside, but persistent losses and high valuation ratios pose significant risks. Investment opportunity hinges on revenue growth translating to profitability, while key risks include execution challenges and competitive pressures in the biotechnology sector.
JPST trades at $50.27, up 0.04% with a bearish technical signal from moving averages. The ETF shows neutral oscillators like RSI near 35, while recent news highlights institutional selling and mixed sentiment on its yield competitiveness. Dividend payments of $0.17 are scheduled through October 2026, but key financial ratios are unavailable for fundamental assessment.
Outlook remains cautious due to technical weakness and underperformance concerns cited by analysts. Risks include interest rate sensitivity and expense ratios, but demand for ultra-short income ETFs amid market volatility offers stability. Investors should weigh yield against peer comparisons and fee structures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About JPMorgan Ultra Short Income ETF
JPST is an actively managed ETF that invests in short-term, investment-grade fixed income securities. It aims to provide current income and capital preservation while maintaining high liquidity.
Read more on JPST →
